2026
Pacific Edge Placement Increased to NZ $25.4 Million
Pacific Edge Limited (Pacific Edge or the Company) (NZX/ASX: PEB) today announces it has successfully raised NZ$25.4 million of new equity in a placement of new ordinary shares (Placement), after the Directors resolved to increase the Placement and accept oversubscriptions following strong investor demand. [read more]
Pacific Edge FY26 Result To Be Announced 25 May 2026
Pacific Edge today advises that its full year results for the 12 months to 31 March 2026 (FY26) will be released on Monday 25 May 2026, prior to 10am. [read more]
Pacific Edge Launches Capital Raise of NZ$24 Million
Cancer diagnostics company Pacific Edge (NZX, ASX: PEB, the ‘Company’) today announces an offer to raise up to NZ$24 million at NZ$0.170 per share consisting of a placement of NZ$18 million new ordinary shares to eligible investors and an offer of NZ$6 million new shares to retail investors with an ability to accept over subscriptions. [read more]
Q4 26 Test Volumes Rise with Medicare Policy Momentum
Pacific Edge today releases its investor update for the three months to the end of March 2026 (Q4 26) today showing an increase in test volumes as strategic momentum for a Medicare policy change mounts. [read more]
First Triage Plus Tests Ordered From Townsville
Pacific Edge announces today that after 11 referrals for Cxbladder were sent to patients last week, the first Triage Plus test has now been ordered by Townsville University Hospital, Queensland, according to an agreed clinical pathway. [read more]
Leading Singapore Hospital Now Ordering Cxbladder
Pacific Edge today announces its Dunedin laboratory has signed a service agreement with Singapore General Hospital (SGH), an important milestone in the company’s strategy to drive the adoption of its tests in the Asia Pacific. [read more]
Expert Panel Expresses Clear Support for Urine-Based Biomarkers in Hematuria Evaluation
Pacific Edge today summarizes the opinions expressed by the panel of experts during the Contractor Advisory Committee (CAC) meeting organized by Novitas on Thursday 19 February 2026 (US time) regarding the use of urine-based biomarker tests in the evaluation of hematuria. [read more]
Medicare Contractor Novitas Schedules Expert Panel
Pacific Edge notes its Medicare Administrative Contractor (MAC) Novitas has confirmed the scheduling of its planned Contractor Advisory Committee (CAC) to consider the evidence for urine biomarkers in patients with hematuria. [read more]
Kaiser Study Backs Triage Ahead of Medicare Panel
Pacific Edge welcomes the publication, in the journal 'Urology Practice', of a Kaiser Permanente study demonstrating the real-world Clinical Utility of Cxbladder Triage in the largest ever urine-based biomarker study on patients presenting with hematuria. [read more]
Q3 26 Results and Key Strategic Milestones
Pacific Edge releases its Investor Update for the three months to the end of December 2025 (Q3 26) today with reports on further strategic achievements to support a reinstatement of Medicare coverage of Cxbladder and the volume of Cxbladder tests processed through its laboratories. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.
